{"filing":{"accession_number":"0001837607-26-000057","cik":"0001837607","ticker":"AEON","company_name":"AEON Biopharma, Inc.","form":"8-K","filing_date":"2026-08-03","report_date":"2026-08-03","primary_document":"aeon-20260803x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1837607/000183760726000057/aeon-20260803x8k.htm"},"events":[{"id":23460,"run_id":21210,"accession_number":"0001837607-26-000057","anchor_item_number":"8.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"summary":"AEON Biopharma announced it has regained compliance with NYSE American's continued listing standards after resolving stockholders' equity deficiencies under Sections 1003(a)(i) and 1003(a)(ii) of the NYSE American Company Guide. The company received written notice from NYSE Regulation confirming resolution of the deficiencies and expects removal of the '.BC' (below compliance) indicator from its trading symbol.","company_name":"AEON Biopharma, Inc.","ticker":"AEON","filing_date":"2026-08-03","form":"8-K","submitted_at":null,"items":[{"id":23689,"accession_number":"0001837607-26-000057","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"AEON Biopharma announced it has regained compliance with NYSE American's continued listing standards after previously being in violation of stockholders' equity requirements under Sections 1003(a)(i) and 1003(a)(ii) of the NYSE American Company Guide. The company received written notice confirming resolution of deficiencies and expects removal of the \".BC\" (below compliance) indicator from its trading symbol. This disclosure directly addresses delisting risk—the company was previously at risk of delisting due to insufficient stockholders' equity and has now remedied that condition through a public offering that raised approximately $13.6 million in net proceeds.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:33:49.856842+00:00","company_name":"","ticker":null,"filing_date":""},{"id":23690,"accession_number":"0001837607-26-000057","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"AEON received written notice from NYSE Regulation on August 3, 2026, confirming that it has \"regained compliance\" with NYSE American's continued listing standards after resolving deficiencies under Sections 1003(a)(i) and (ii) of the Company Guide relating to stockholders' equity. The \".BC\" (below compliance) indicator will be removed from the trading symbol. This is a material delisting-risk event because it documents the resolution of a prior listing deficiency that threatened continued listing; the company was previously noncompliant and has now cured that status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:33:49.856842+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":23689,"accession_number":"0001837607-26-000057","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"AEON Biopharma announced it has regained compliance with NYSE American's continued listing standards after previously being in violation of stockholders' equity requirements under Sections 1003(a)(i) and 1003(a)(ii) of the NYSE American Company Guide. The company received written notice confirming resolution of deficiencies and expects removal of the \".BC\" (below compliance) indicator from its trading symbol. This disclosure directly addresses delisting risk—the company was previously at risk of delisting due to insufficient stockholders' equity and has now remedied that condition through a public offering that raised approximately $13.6 million in net proceeds.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:33:49.856842+00:00","company_name":"AEON Biopharma, Inc.","ticker":"AEON","filing_date":"2026-08-03"},{"id":23690,"accession_number":"0001837607-26-000057","item_number":"8.01","item_title":"Other Events.","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.92,"reasoning":"AEON received written notice from NYSE Regulation on August 3, 2026, confirming that it has \"regained compliance\" with NYSE American's continued listing standards after resolving deficiencies under Sections 1003(a)(i) and (ii) of the Company Guide relating to stockholders' equity. The \".BC\" (below compliance) indicator will be removed from the trading symbol. This is a material delisting-risk event because it documents the resolution of a prior listing deficiency that threatened continued listing; the company was previously noncompliant and has now cured that status.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-04T02:33:49.856842+00:00","company_name":"AEON Biopharma, Inc.","ticker":"AEON","filing_date":"2026-08-03"}]}